UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  December 9, 2004

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-26642

 

87-0494517

(State or other
jurisdiction of
incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

320 Wakara Way
Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 584-3600

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 8.01             Other Events

 

On December 9, 2004, Myriad Genetics, Inc. announced that it has submitted an Investigational New Drug (IND) application to the FDA to begin a Phase I clinical study with its pro-apoptotic cancer drug candidate, MPC-6827.  The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.

 

ITEM 9.01             Financial Statements and Exhibits.

 

(c)           The following exhibit is filed with this report:

 

Exhibit
Number

 

Description

 

 

 

99.1

 

The Registrant’s press release dated December 9, 2004.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MYRIAD GENETICS, INC.

 

 

 

 

Date: December 9, 2004

By:

/s/ Peter D. Meldrum

 

 

 

Peter D. Meldrum

 

 

President and Chief Executive Officer

 

3


 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

 

 

 

99.1

 

The Registrant’s press release dated December 9, 2004.

 

4